ScreenerHero

IVA Inventiva S.A.

EPA · FR · Healthcare · Biotechnology · inventivapharma.com
3.010EUR-4.29%Mkt Cap: 772.85M $P/E: —

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap772.85M USD
Enterprise Value778.00M USD
Revenue (TTM)2.67M USD
Gross Profit2.09M USD
Net Income (TTM)-384.93M USD
Revenue/Share0.0090 EUR
Last Price3.010 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013233012
Valuation
P/E (Trailing)—
P/E (Forward)-5.28
PEG—
EV/EBITDA-4.80
EV/Revenue291.43
P/S302.49
P/B12.58
EPS (TTM)-0.53
EPS (Forward)-0.60
52W Range
2.7308% of range6.200
52W High6.200 EUR
52W Low2.730 EUR
Profitability
Gross Margin78.26%
Oper. Margin-5337.32%
EBITDA Margin0.00%
Profit Margin-7899.58%
ROE1241.63%
ROA-141.93%
Growth
Revenue Growth-76.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-114.00M USD
CapEx (TTM)268.48K USD
FCF Margin-4727.97%
FCF Yield-16.33%
Net Debt-29.72M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity-2.10
Current Ratio3.81
Quick Ratio2.73
Book Value/Sh0.25 EUR
Cash/Share0.70 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.770 EUR
Upside (mean)+224.6%
Target Range6.600 EUR – 15.48 EUR
6.600+224.6% to mean15.48
# Analysts4
Ownership
Shares Out.236.22M
Float165.57M
Insiders12.63%
Institutions50.05%
Technical
SMA 503.720 (-19.1%)
SMA 2004.305 (-30.1%)
Beta0.92
S&P 52W Chg14.58%
Avg Vol (30d)618.09K
Avg Vol (10d)876.16K
Technical Indicators
RSI (14)39.8
MACD-0.2129
MACD Signal-0.2264
MACD Hist.+0.0135
BB Upper3.889 EUR
BB Middle3.237 EUR
BB Lower2.584 EUR
BB Width40.31%
ATR (14)0.2305 EUR
Vol Ratio (20d)0.93x